Ixekizumab for treatment of psoriasis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Ixekizumab for treatment of psoriasis. / Dyring-Andersen, Beatrice; Skov, Lone; Zachariae, Claus.

In: Expert Review of Clinical Immunology, Vol. 11, No. 4, 04.2015, p. 435-42.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Dyring-Andersen, B, Skov, L & Zachariae, C 2015, 'Ixekizumab for treatment of psoriasis', Expert Review of Clinical Immunology, vol. 11, no. 4, pp. 435-42. https://doi.org/10.1586/1744666X.2015.1023295

APA

Dyring-Andersen, B., Skov, L., & Zachariae, C. (2015). Ixekizumab for treatment of psoriasis. Expert Review of Clinical Immunology, 11(4), 435-42. https://doi.org/10.1586/1744666X.2015.1023295

Vancouver

Dyring-Andersen B, Skov L, Zachariae C. Ixekizumab for treatment of psoriasis. Expert Review of Clinical Immunology. 2015 Apr;11(4):435-42. https://doi.org/10.1586/1744666X.2015.1023295

Author

Dyring-Andersen, Beatrice ; Skov, Lone ; Zachariae, Claus. / Ixekizumab for treatment of psoriasis. In: Expert Review of Clinical Immunology. 2015 ; Vol. 11, No. 4. pp. 435-42.

Bibtex

@article{6ee9cbf738b04d51be28c5ffa77bf10e,
title = "Ixekizumab for treatment of psoriasis",
abstract = "Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.",
keywords = "Animals, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Humans, Interleukin-17, Molecular Targeted Therapy, Protein Binding, Psoriasis, Receptors, Interleukin-17, Skin",
author = "Beatrice Dyring-Andersen and Lone Skov and Claus Zachariae",
year = "2015",
month = apr,
doi = "10.1586/1744666X.2015.1023295",
language = "English",
volume = "11",
pages = "435--42",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Ixekizumab for treatment of psoriasis

AU - Dyring-Andersen, Beatrice

AU - Skov, Lone

AU - Zachariae, Claus

PY - 2015/4

Y1 - 2015/4

N2 - Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

AB - Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

KW - Animals

KW - Antibodies, Monoclonal, Humanized

KW - Clinical Trials as Topic

KW - Humans

KW - Interleukin-17

KW - Molecular Targeted Therapy

KW - Protein Binding

KW - Psoriasis

KW - Receptors, Interleukin-17

KW - Skin

U2 - 10.1586/1744666X.2015.1023295

DO - 10.1586/1744666X.2015.1023295

M3 - Journal article

C2 - 25748485

VL - 11

SP - 435

EP - 442

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 4

ER -

ID: 161852658